Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BiomX ( (PHGE) ) just unveiled an announcement.
On December 26, 2025, BiomX Inc. entered into a Securities Purchase Agreement with a single investor for a private placement of 3,300 shares of newly created Series Y Convertible Preferred Stock, with an aggregate stated value of $3.3 million, and accompanying warrants to purchase 3,300,000 shares of common stock, for expected gross proceeds of $3.0 million before fees. The Series Y Preferred Stock carries a 15% annual dividend payable in cash or stock, ranks senior to common stock and existing Series X preferred stock, has a one-year maturity, and is initially convertible at $2.00 per share, while the warrants are immediately exercisable at $2.00 per share for five years, with both instruments subject to price adjustments and a 19.99% beneficial ownership cap until stockholder approval is obtained. As part of the deal, the investor secured board representation rights tied to ownership thresholds, BiomX committed to seek stockholder approval within 60 days to permit issuance of more than 19.99% of its outstanding common shares, and it granted registration rights for resale of the underlying securities, signaling a significant equity financing that could meaningfully dilute existing shareholders but strengthens the company’s balance sheet and brings in an influential strategic investor; H.C. Wainwright & Co. acted as exclusive placement agent and will receive fees and additional warrants, and the transaction is expected to close on or about December 30, 2025, subject to customary conditions.
The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. is a Delaware-incorporated company whose securities trade on the NYSE American and that raises capital through private placements of preferred stock and warrants, indicating a focus on financing its operations and growth via structured equity transactions in the public capital markets.
Average Trading Volume: 83,804
Technical Sentiment Signal: Sell
Current Market Cap: $2.95M
See more insights into PHGE stock on TipRanks’ Stock Analysis page.